In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc. KYNAMRO™ is a trademark of Genzyme Corporation.
ISIS PHARMACEUTICALS, INC.SELECTED FINANCIAL INFORMATIONCondensed Consolidated Statements of Operations
(In Thousands, Except Per Share Data)Three months ended,Six months ended,June 30,June 30,2013201220132012Revenue:(unaudited)(unaudited)Research and development revenue under collaborative agreements$37,615$47,140$79,535$68,957Licensing and royalty revenue4772001,9161,618Total revenue38,09247,34081,45170,575Expenses:Research and development 42,63140,43580,94479,149General and administrative 3,3893,2096,8116,185Total operating expenses46,02043,64487,75585,334Income (loss) from operations(7,928)3,696(6,304)(14,759)Other income (expense):Equity in net loss of Regulus Therapeutics Inc.-(163)-(1,139)Investment income5894779671,077Interest expense(4,808)(5,219)(9,603)(10,398)Gain on investments, net84021,89819Loss before income tax benefit (expense)(11,307)(1,207)(13,042)(25,200)Income tax benefit (expense)1,181-1,244(2)Net loss $(10,126)$(1,207)$(11,798)$(25,202)Basic and diluted net loss per share$(0.09)$(0.01)$(0.11)$(0.25)Shares used in computing basic and diluted net loss per share108,539100,213105,225100,185 Isis Pharmaceuticals, Inc.Reconciliation of GAAP to Pro Forma Basis: Condensed Consolidated Operating Expenses and (Income) Loss From Operations (In Thousands)
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved